Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia: early-phase trial registry
51 of 274 indexed Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #35 of 28,707 conditions by registered trial count.
274 US clinical trials · 51 currently recruiting · #35 of 28,707 conditions by registered trial count
Leukemia: 274 US clinical trials tracked, 51 recruiting.
Leukemia is the subject of 274 registered US clinical trials on ClinicalTrials.gov, 51 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 193 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 37 of these trials.
Enrollment posture brief
Registry condition leukemia
OPEN 51 | RECR 19% | LATE 19 | EARLY 193 | RANK #35 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Rheumatoid Arthritis (19% recruiting · 199 trials)
Leukemia lists 51 open slots (19% of 274 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia is recruiting below its size-band peers.
51 of 274 indexed trials (18.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 37 of 274 trials (13.5%). 84 distinct sponsors appear on at least one study for this condition label.
-
Most Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 234 trials that report a genuine target (sentinel values excluded). 170 of those (72.6%) plan for fewer than 100 participants.
-
Leukemia research is mostly interventional.
243 interventional and 31 observational studies make up this index (88.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
274 total, page 1 of 6
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137643
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Children's Oncology Group
NCT00736749
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01137825
HEME Home Transfusion Program
Dana-Farber Cancer Institute
NCT06487247
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo
NCT06578247
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
NCT00582621
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
UNC Lineberger Comprehensive Cancer Center
NCT06296368
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
University of Miami
NCT05745285
Mosaic Trial for Stem Cell Transplant Recipients
Northwestern University
NCT06960993
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
Dana-Farber Cancer Institute
NCT04968834
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
NCT06870760
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology
NCT06001788
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
NCT06501196
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT01515527
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
Children's Hospital Los Angeles
NCT06360718
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Daiichi Sankyo
NCT06824168
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Hannah Choe, MD
NCT07249346
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
University of Chicago
NCT07294677
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
University of Arizona
NCT06643221
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Children's Hospital of Philadelphia
NCT02356653
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT06839456
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05011045
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Massachusetts General Hospital
NCT05646576
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
National Cancer Institute (NCI)
NCT06856226
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
University of Nebraska
NCT04898790
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Dana-Farber Cancer Institute
NCT03319901
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Dana-Farber Cancer Institute
NCT06907797
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
University of Chicago
NCT07405424
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD
NCT06644183
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
NCT07052916
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
NCT05536349
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
National Cancer Institute (NCI)
NCT05237986
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT07356154
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Dana-Farber Cancer Institute
NCT06469307
Mosunetuzumab for CLL MRD Clearance
Inhye Ahn
NCT07052695
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
M.D. Anderson Cancer Center
NCT01608152
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
M.D. Anderson Cancer Center
NCT06229912
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
NCT05794880
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Jacqueline Garcia, MD
NCT07148180
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Massachusetts General Hospital
NCT05842603
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado, Denver
NCT06429449
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
St. Jude Children's Research Hospital
NCT06810583
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT05645718
Revumenib in Combination With 7+3 + Midostaurin in AML
Richard Stone, MD
NCT06313437
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
NCT03826992
Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
University of Colorado, Denver
NCT05425992
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
NCT06408194
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT06138587
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
NCT06152809
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 95 |
| Phase 3 | 18 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia page
274 registered trials, 51 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 51 Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia condition card totals 274 registered trials; most-linked intervention cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.